Effect of avandamet on conditioned food reflex in rats of different age groups
V.A. Gorbachenko, Zh.O. Kruchenko, E.A. Lukyanetz
O.O. Bogomoletz Institute of Physiology, NAS Ukraine, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz66.06.041
Abstract
The prevalence of Alzheimer’s disease (AD) is increasing in the absence of truly effective treatments. The
recently discovered causal link between AD and type 2 diabetes mellitus (T2DM) (non-insulin-dependent
diabetes mellitus) suggests that an increase in insulin receptor resistance may affect brain aging and lead to
AD. In our experiments, we tested Avandamet (AVD), the antidiabetic drug used for the treatment of T2DM,
on temporary parameters of conditioning food reflex in rats. We measured the individual components of the
sensorimotor reaction (SMR) of rats, which reflect CNS’s functional state. Important tha7t rosiglitazone is
the main component of AVD. It acts by activating the nuclear peroxisome proliferator-activated receptor
(PPAR) gamma. Our data showed that this drug influences the brain function of both young and old rats. It is
proved that AVD affects the CNS of rats by increasing their excitability. Considering the obtained data from
the point of view of AD, the time parameter, which changed more significantly in old rats, was responsible
for analyzing the situation and speed of action. Under AVD’s influence, old rats became more agile and had
increased motor activity, also the success of rats in performing a conditioned reflex was increased. Thus,
the drug AVD and its active component rosiglitazone can be perspective for its testing in AD treatment.
Keywords:
Alzheimer’s disease; avandamet; behavior; conditioning reflex; food reflex; rats; PPAR; rosiglitazone
References
- Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol. 2011;71(3):365-76.
CrossRef
PubMed PubMedCentral
- McIntyre RS, Soczynska JK, Lewis GF, MacQueen GM, Konarski JZ, Kennedy SH. Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opinion Pharmacother. 2006;7(10):1305-21.
CrossRef
PubMed
- Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53(2):474.
CrossRef
PubMed
- Cao B, Rosenblat JD, Brietzke E, Park C, Lee Y, Musial N, et al. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis. Diabetes, Obesity Metab. 2018;20(10):2467-71.
CrossRef
PubMed
- Pilipenko V, Narbute K, Pupure J, Langrate IK, Muceniece R, Kluša V. Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer's disease. Eur J Pharmacol. 2020:173290.
CrossRef
PubMed
- Li H, Wu J, Zhu L, Sha L, Yang S, Wei J, et al. Insulin degrading enzyme contributes to the pathology in a mixed model of type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD. Biosci Reports. 2018;38(1).
CrossRef
PubMed PubMedCentral
- de Nazareth AM. Type 2 diabetes mellitus in the pathophysiology of Alzheimer's disease. Dement Neuropsychol. 2017;11(2):105-13.
CrossRef
PubMed PubMedCentral
- Tumminia A, Vinciguerra F, Parisi M, Frittitta L. Type 2 diabetes mellitus and Alzheimer's disease: Role of insulin signalling and therapeutic implications. Int J Mol Sci. 2018;19(11):3306.
CrossRef
PubMed PubMedCentral
- Mittal K, Katare DP. Shared links between type 2 diabetes mellitus and Alzheimer's disease: A review. Diabetes Metablic Syndrome: Clinical Research & Reviews. 2016;10(2, Suppl 1):S144-S9.
CrossRef
PubMed
- Chatterjee S, Mudher A. Alzheimer's disease and type 2 diabetes: A critical assessment of the shared pathological traits. Front Neurosci. 2018;12:383.
CrossRef
PubMed PubMedCentral
- Caberlotto L, Nguyen TP, Lauria M, Priami C, Rimondini R, Maioli S, et al. Cross-disease analysis of Alzheimer's disease and type-2 diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseases. Sci Reports. 2019;9(1):3965.
CrossRef
PubMed PubMedCentral
- Kamal MA, Priyamvada S, Anbazhagan AN, Jabir NR, Tabrez S, Greig NH. Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation. CNS Neurol Disord Drug Targets. 2014;13(2):338-46.
CrossRef
PubMed PubMedCentral
- Sarathlal K CS, Kakoty V, Marathe S, Chitkara D, Taliyan R. Exploring the neuroprotective potential of rosiglitazone embedded nanocarrier system on streptozotocin induced mice model of Alzheimer's disease. Neurotoxic Res. 2020.
- Denner LA, Rodriguez-Rivera J, Haidacher SJ, Jahrling JB, Carmical JR, Hernandez CM, et al. Cognitive enhancement with rosiglitazone links the hippocampal PPARγ and ERK MAPK signaling pathways. J Neurosci: the official journal of the Society for Neuroscience. 2012;32(47):16725-35a.
CrossRef
PubMed PubMedCentral
- Xu S, Guan Q, Wang C, Wei X, Chen X, Zheng B, et al. Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses. Neurosci Lett. 2014;578:7-11.
CrossRef
PubMed
- Gorbachenko V, Chereda I, Vrublevsky S, Kruchenko J, Lukyanetz E. Development and testing of the experimental system for registration of food reflex in rats. Bull Taras Shevchenko Natl Univ Kyiv Ser: Radiophysics and Electronics. 2014;1/2(21/22):31-3.
- Gorbachenko VA, Kruchenko JO, Chereda IS, Lukyanetz EA. Measurements of the time parameters of conditioned food reflex in rats under memantin treatment with using of automatic registration system. Bull Taras Shevchenko Natl Univ KyivSer: Radiophysics and Electronics. 2015;1(23):23-6.
- Kravenska EV, Ganzha VV, Yavorskaya EN, Lukyanetz EA. Effect of cyclosporin A on the viability of hippocampal cells cultured under conditions of modeling of Alzheimers disease. Neurophysiology. 2016;48(4):246-51.
CrossRef
- Kravenska Y, Nieznanska H, Nieznanski K, Lukyanetz E, Szewczyk A, Koprowski P. The monomers, oligomers, and fibrils of amyloid-β inhibit the activity of mitoBKCa channels by a membrane-mediated mechanism. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2020;1862(9):183337.
CrossRef
PubMed
- Kostiuk OP, Korol T, Korol SV, Romanenko SV, Pinchenko VO, Kostiuk PH. [Alteration of calcium signaling as one of the mechanisms of Alzheimer's disease and diabetic polyneuropathy]. Fiziol Zh (Kiev, Ukraine: 1994). 2010;56(4):130-8.
CrossRef
- Korol T, Kostiuk OP, Kostiuk PH. [Effect of beta-amyloid protein on calcium channels in plasma membranes of cultured hippocampal neurons]. Fiziol Zh (Kiev, Ukraine:1994). 2009;55(4):10-6.
CrossRef
- Kruchenko ZA, Gorbachenko VA, Chereda IS, Lukyanetz EA. Effect of memantine on motor behavioral phenomena in rats of different ages. Neurophysiology. 2014;46(5):448-51.
CrossRef
- Tyshchenko Y, Lukyanetz EA. Effects of memantine on behavioral indices of rats in the open field. Neurophysiology. 2017;49(6):453-7.
CrossRef
- DiTacchio KA, Heinemann SF, Dziewczapolski G. Metformin treatment alters memory function in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2015;44(1):43-8.
CrossRef
PubMed
- Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011;2(4):236-40.
CrossRef
PubMed PubMedCentral
- Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-35.
CrossRef
PubMed
- Nierenberg AA, Ghaznavi SA, Sande Mathias I, Ellard KK, Janos JA, Sylvia LG. Peroxisome Proliferatoractivated receptor gamma coactivator-1 alpha as a novel target for bipolar disorder and other neuropsychiatric disorders. Biol Psychiat. 2018;83(9):761-9.
CrossRef
PubMed
|